Literature DB >> 130494

Effect of PS-K, a protein polysaccharide, on pulmonary metastases of a C3H mouse squamous cell carcinoma.

S Usui, M Urano, S Koike, Y Kobayashi.   

Abstract

We studied the effects of PS-K, a protein polysaccaride isolated from a basidiomycete, on the formation of blood-borne metastases. Experimental tumors were fifth-generation isotransplants of a spontaneous C3Hf mouse squamous cell carcinoma that was weakly antigenic. A single-cell suspension from fourth generation tumors was transplanted, and the tumor-bearing legs of the mice were amputated when transplants reached a certain diameter. Daily administrations of PS-K followed immediately, and both lungs were excised on the 21st postamputation day. The number of lung colonies formed on the surfaces of both lungs was counted and total volumes of metastatic colonies were estimated. PS-K, if administered alone, did not inhibit the lung colony formation. Marked reduction in this formation was observed when five daily doses of PS-K were administered simultaneously with cyclophosphamide. These observations indicate that PS-K may be a potent agent in the therapy of cancer if used as an adjuvant to a chemotherapeutic agent.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 130494     DOI: 10.1093/jnci/56.1.185

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  9 in total

1.  Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma.

Authors:  Goichi Matsumoto; Nobuyuki Yajima; Hiroyuki Saito; Hironori Nakagami; Yasushi Omi; Ushaku Lee; Yasufumi Kaneda
Journal:  Clin Exp Metastasis       Date:  2010-07-10       Impact factor: 5.150

2.  Antitumor and antimetastatic activity of the immunoadjuvant peptidoglycan monomer PGM in mice bearing MCa mammary carcinoma.

Authors:  G Sava; J Tomasic; I Hrsak
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

3.  Tumour rejection by gene transfer of 4-1BB ligand into a CD80(+) murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells.

Authors:  S Mogi; J Sakurai; T Kohsaka; S Enomoto; H Yagita; K Okumura; M Azuma
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

4.  Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles.

Authors:  Rodney Macedo; Juliette Rochefort; Maude Guillot-Delost; Kae Tanaka; Aline Le Moignic; Clara Noizat; Claude Baillou; Véronique Mateo; Antoine F Carpentier; Eric Tartour; Chloé Bertolus; Bertrand Bellier; Géraldine Lescaille; François M Lemoine
Journal:  Oncoimmunology       Date:  2016-07-06       Impact factor: 8.110

5.  The therapeutic effects of an immunopotentiator, PS-K, on 3-methylcholanthrene-induced autochthonous tumors in C57BL/6 mice in combination with the surgical removal of primary sites.

Authors:  M Hosokawa; T Mizukoshi; K Morikawa; Z Y Xu; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Combined therapeutic effects of an immunomodulator, PSK, and chemotherapy with carboquone on rat bladder carcinoma.

Authors:  D D Mickey
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka; N Okada; M Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

8.  Effects of BCG, levamisole and PS-K on the rejection of male skin grafts by female mice.

Authors:  S Seo; J Yasuhara; K Saeki
Journal:  Agents Actions       Date:  1979-10

9.  Role of first stimulating agents in the production of tumor necrosis factor.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.